CA
NZ
UK
AU
IND
US
…
IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States. The company offers integrated services, including development, analytical testing, clinical packaging; and microbiological and analytical testing, clinical packaging, and pharmacy services. It also provides formulation and manufacture of speciality orals (medicinal cannabis) and advanced therapies; psychedelics and medicinal cannabis; oral finished doses; and aseptic fill and finish solutions for liquid and lyophilised forms. In addition, the company offers mRNA and antibody drug conjugates. Further, the company provides contract manufacturing services. IDT Australia Limited was founded in 1975 and is headquartered in Boronia, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
IDT Australia Ltd is an ASX-listed life sciences company; publicly available detail on its operations is limited and investors should consult the company’s filings for specifics. Company disclosures point to a focus on developing therapeutic candidates and pursuing commercialisation or licensing outcomes, which could support long-term growth and may benefit investors seeking exposure to milestone-driven biotech upside.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -2.70M | -8.06M | -6.08M | -9.78M | -1.88M |
| Net income | -2.72M | -8.06M | -5.41M | -8.50M | -1.16M |
| Selling general administrative | 11.31M | 0.61M | 1.39M | 9.78M | 7.08M |
| Selling and marketing expenses | - | 14.69M | 10.62M | - | - |
| Gross profit | 4.29M | 9.69M | 10.42M | 4.75M | 10.66M |
| Reconciled depreciation | 0.90M | 0.86M | 0.93M | 1.04M | 1.54M |
| Ebit | -1.65M | -7.40M | -6.49M | -9.87M | -1.90M |
| Ebitda | -0.74M | -6.54M | -5.56M | -8.83M | -0.36M |
| Depreciation and amortization | 0.90M | 0.86M | 0.93M | 1.04M | 1.54M |
| Operating income | -1.65M | -6.31M | -6.85M | -9.78M | -1.88M |
| Other operating expenses | 22.00M | 26.08M | 20.08M | -6.03M | -4.48M |
| Interest expense | 1.25M | 0.76M | 0.12M | - | 0.03M |
| Tax provision | 0.00M | 0.00M | -0.66M | -1.28M | -0.72M |
| Interest income | 0.15M | 0.10M | 0.10M | - | - |
| Net interest income | -1.10M | -0.66M | -0.02M | - | - |
| Income tax expense | 0.02M | -0.24M | -0.66M | -1.28M | -0.72M |
| Total revenue | 20.36M | 19.77M | 13.23M | 6.93M | 12.11M |
| Total operating expenses | 5.94M | 16.01M | 17.27M | 14.63M | 12.57M |
| Cost of revenue | 16.06M | 10.07M | 2.81M | 2.18M | 1.44M |
| Total other income expense net | -1.05M | -1.75M | 0.78M | 0.10M | 0.03M |
| Net income from continuing ops | -2.72M | -8.06M | -5.41M | -8.50M | -1.16M |
| Net income applicable to common shares | - | -8.06M | -5.41M | -8.50M | -1.16M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 34.89M | 36.92M | 31.37M | 28.29M | 30.08M |
| Intangible assets | - | - | - | 0.00M | 0.00M |
| Other current assets | 1.68M | 1.41M | 1.65M | 0.19M | 0.05M |
| Total liab | 15.85M | 15.03M | 7.93M | 4.15M | 3.09M |
| Total stockholder equity | 19.04M | 21.89M | 23.44M | 24.14M | 26.99M |
| Other current liab | 1.59M | 2.34M | 2.30M | 0.83M | 0.15M |
| Common stock | 64.19M | - | 57.70M | 54.93M | 51.19M |
| Capital stock | 64.19M | 64.19M | - | 54.93M | 51.19M |
| Retained earnings | -57.75M | -55.04M | -46.97M | -41.56M | -32.70M |
| Other liab | - | - | - | 0.17M | 0.31M |
| Cash | 2.52M | 0.50M | 0.50M | 4.43M | 9.21M |
| Total current liabilities | 5.57M | 5.29M | 7.76M | 3.98M | 2.78M |
| Current deferred revenue | 2.64M | - | 0.33M | 2.07M | 1.19M |
| Net debt | 8.31M | 9.90M | 3.96M | -3.69M | -8.33M |
| Short term debt | 0.74M | - | 4.47M | 0.74M | 0.88M |
| Short long term debt | 0.74M | 0.82M | - | 0.74M | 0.88M |
| Short long term debt total | 10.82M | - | 4.47M | 0.74M | 0.88M |
| Other stockholder equity | - | - | - | -13.37M | -18.13M |
| Property plant equipment | - | - | - | 18.55M | 16.21M |
| Total current assets | 12.99M | 15.52M | 10.41M | 9.74M | 13.87M |
| Net tangible assets | - | - | - | 24.14M | 26.99M |
| Short term investments | 0.10M | 3.60M | - | - | - |
| Net receivables | 6.17M | 5.42M | 6.57M | 2.25M | 1.54M |
| Long term debt | 10.09M | 9.59M | - | - | - |
| Inventory | 2.63M | 3.03M | 1.68M | 1.37M | 1.10M |
| Accounts payable | 0.60M | 0.75M | 0.66M | 0.35M | 0.55M |
| Accumulated other comprehensive income | 12.61M | - | 12.71M | 10.77M | 8.50M |
| Non currrent assets other | 0.09M | - | - | -18.55M | -16.21M |
| Non current assets total | 21.90M | 21.40M | 20.96M | 18.55M | 16.21M |
| Long term debt total | - | - | - | 0.00M | 0.00M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | 3.50M | -4.50M | -1.09M | -0.52M | -0.91M |
| Change to liabilities | - | - | - | -1.19M | -1.25M |
| Total cashflows from investing activities | 2.19M | -4.50M | -1.09M | -0.52M | -0.91M |
| Net borrowings | -1.31M | 4.10M | 3.73M | -0.14M | 0.02M |
| Total cash from financing activities | -1.25M | 10.75M | 6.77M | 3.64M | 0.34M |
| Change to operating activities | - | - | - | 0.20M | 0.28M |
| Net income | -2.72M | -8.06M | -5.41M | -8.50M | -1.16M |
| Change in cash | 2.01M | -0.00M | -3.93M | -4.78M | 2.29M |
| Begin period cash flow | 0.50M | 0.50M | 4.43M | 9.21M | 6.93M |
| End period cash flow | 2.52M | 0.50M | 0.50M | 4.43M | 9.21M |
| Total cash from operating activities | 1.07M | -6.25M | -9.60M | -7.90M | 2.86M |
| Issuance of capital stock | 0.06M | 6.65M | 3.04M | 3.78M | 0.32M |
| Depreciation | 0.90M | 0.86M | 0.93M | -1.04M | -1.54M |
| Other cashflows from investing activities | - | -3.20M | -0.40M | - | 0.00M |
| Change to inventory | 0.40M | -1.35M | -0.31M | 0.27M | -0.70M |
| Change to account receivables | 0.33M | -0.51M | -3.74M | 1.00M | 7.10M |
| Sale purchase of stock | - | 6.65M | 3.04M | 3.78M | 0.32M |
| Other cashflows from financing activities | - | - | -1.09M | 1.23M | 1.35M |
| Change to netincome | - | - | - | 0.18M | 0.32M |
| Capital expenditures | 1.31M | 1.30M | 0.69M | 0.52M | 0.91M |
| Change in working capital | 1.60M | -1.82M | -4.40M | 1.27M | 6.40M |
| Stock based compensation | - | - | -0.06M | 0.18M | 0.32M |
| Other non cash items | 1.28M | 2.78M | -0.66M | 1.63M | 5.56M |
| Free cash flow | -0.24M | -7.55M | -10.30M | -8.42M | 1.95M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IDT IDT Australia Ltd |
- -% |
0.04 | - | 4.63 | 0.84 | 0.90 | 1.25 | -1.02 |
| AFP Aft Pharmaceuticals Ltd |
-0.04 1.11% |
3.55 | 29.92 | 18.18 | 1.48 | 4.37 | 2.05 | 18.56 |
| VLS Vita Life Sciences Ltd |
-0.06 2.22% |
2.64 | 13.50 | 42.73 | 1.52 | 2.62 | 1.19 | 7.17 |
| LGP Little Green Pharma Ltd |
-0.00 1.72% |
0.06 | - | 10.00 | 0.64 | 0.60 | 1.25 | 19.47 |
| MVP Medical Developments International Ltd |
0.01 3.75% |
0.41 | 40.00 | 166.67 | 1.06 | 0.79 | 0.57 | 7.45 |
IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States. The company offers integrated services, including development, analytical testing, clinical packaging; and microbiological and analytical testing, clinical packaging, and pharmacy services. It also provides formulation and manufacture of speciality orals (medicinal cannabis) and advanced therapies; psychedelics and medicinal cannabis; oral finished doses; and aseptic fill and finish solutions for liquid and lyophilised forms. In addition, the company offers mRNA and antibody drug conjugates. Further, the company provides contract manufacturing services. IDT Australia Limited was founded in 1975 and is headquartered in Boronia, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Paul McDonald | Interim CEO | NA |
| Mr. Chris Kagiaros | Head of People & Culture | NA |
| Dr. David Sparling BVSc (Hons), GDipAppCGov, L.L.B., LLB (Hons) | Joint company Sec. | NA |
| Mr. Vasanthakumar Mahendran | Interim Chief Financial Officer | NA |
| Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, FGIA, GAICD, GradDip CSP | Company Sec. | 1964 |
| Mr. Paul Anthony McDonald | Chief Executive Officer | NA |
| Mr. Vasanthakumar Mahendran | Chief Financial Officer | NA |
| Mr. Jim Sosic | COO & Operations Director | NA |
| Ms. Priscilla Thiyageas | Quality Director | NA |
| Ms. Paula Coutts | Head of People & Safety | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...